JPH0359078B2 - - Google Patents
Info
- Publication number
- JPH0359078B2 JPH0359078B2 JP57118883A JP11888382A JPH0359078B2 JP H0359078 B2 JPH0359078 B2 JP H0359078B2 JP 57118883 A JP57118883 A JP 57118883A JP 11888382 A JP11888382 A JP 11888382A JP H0359078 B2 JPH0359078 B2 JP H0359078B2
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- collagen
- determined
- molecular weight
- sds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 102000008186 Collagen Human genes 0.000 claims description 17
- 108010035532 Collagen Proteins 0.000 claims description 17
- 229920001436 collagen Polymers 0.000 claims description 17
- 239000000872 buffer Substances 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 229920002684 Sepharose Polymers 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000001155 isoelectric focusing Methods 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- -1 isooctyl phenyl Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000000903 blocking effect Effects 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 10
- 208000007536 Thrombosis Diseases 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 210000004623 platelet-rich plasma Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- ZTVZLYBCZNMWCF-UHFFFAOYSA-N homocystine Chemical compound [O-]C(=O)C([NH3+])CCSSCCC([NH3+])C([O-])=O ZTVZLYBCZNMWCF-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100205180 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-6 gene Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57118883A JPS5910522A (ja) | 1982-07-07 | 1982-07-07 | 血小板粘着阻止蛋白質及びその製造法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57118883A JPS5910522A (ja) | 1982-07-07 | 1982-07-07 | 血小板粘着阻止蛋白質及びその製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5910522A JPS5910522A (ja) | 1984-01-20 |
| JPH0359078B2 true JPH0359078B2 (enrdf_load_stackoverflow) | 1991-09-09 |
Family
ID=14747490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57118883A Granted JPS5910522A (ja) | 1982-07-07 | 1982-07-07 | 血小板粘着阻止蛋白質及びその製造法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5910522A (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5321127A (en) * | 1991-03-18 | 1994-06-14 | Brigham And Women's Hospital | Antiplatelet and antithrombotic activity of platelet glycoprotein Ib receptor fragments |
-
1982
- 1982-07-07 JP JP57118883A patent/JPS5910522A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5910522A (ja) | 1984-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0503991B1 (fr) | Procédé de préparation à l'échelle industrielle d'un concentré de facteur von Willebrand humain standardisé, de très haute pureté, approprié à un usage thérapeutique | |
| EP2337796B1 (fr) | Proteines recombinantes a activite hemostatique capables d'induire l'agregation plaquett aire | |
| DK155568B (da) | Fremgangsmaade til stabilisering af koagulationsfaktorerne ii, viii, xiii og antithrombin iii samt plasminogen, og saaledes at disse er fibrinogen-fri og fri for risiko for en hepatitis-overfoering | |
| CA2073012C (en) | Method for isolating factor viii | |
| JP5437378B2 (ja) | ヒャッポダ由来のヘモコアグラーゼ | |
| JPS62174023A (ja) | 抗血液凝固物質、その製法及びそれを有効成分とする抗血液凝固剤 | |
| FI95136B (fi) | Menetelmä anneksiinien puhdistamiseksi | |
| JP2008289498A (ja) | 精製されたマルチメラ−ゼ | |
| NO167627B (no) | Fremgangsmaate for rensing av faktor viii:c. | |
| NO324659B1 (no) | Utvinning av von Willebrand-faktor ved kationebytterkromatografi samt preparat inneholdende slik faktor og anvendelse derav. | |
| USH1509H (en) | Heparin enhanced process for separating antihemophilic factor (Factor VIII) and fibronectin from cryoprecipitate | |
| MXPA05000395A (es) | Proceso para la preparacion de fibrinogeno. | |
| CA2009390A1 (en) | Viper venom polypeptides and variants | |
| JPH01250399A (ja) | トリグラミン、血小板凝集抑制性ポリペプチド | |
| JPH02138298A (ja) | ヘビ毒ポリペプチド及び遺伝子発現 | |
| JPS6160614A (ja) | 第８因子製剤およびその製造方法 | |
| KR100589082B1 (ko) | 피브리노겐 정제 | |
| EP1037923B1 (fr) | Procede de preparation par filtration d'une solution de facteur viii securisee viralement | |
| JPH0545600B2 (enrdf_load_stackoverflow) | ||
| JP4233114B2 (ja) | フォン・ブィレブランド因子の治療用フラグメント | |
| WO2014075374A1 (zh) | 尖吻蝮蛇血凝酶-b | |
| JPH0359078B2 (enrdf_load_stackoverflow) | ||
| CN103160485B (zh) | 尖吻蝮蛇血凝酶-c | |
| EP0131579A1 (en) | Purification of antihemophilia factor viii by precipitation with zinc ions | |
| JPH07508989A (ja) | 第９因子の精製 |